Browse

Preventive effect of GV1001 on gemcitabine-induced pancreatic cancer cachexia
Gemcitabine에 의해 유도된 췌장암 악액질에 미치는 GV1001의 예방 효과

DC Field Value Language
dc.contributor.advisor이왕재-
dc.contributor.author전재은-
dc.date.accessioned2017-07-19T10:34:20Z-
dc.date.available2017-07-19T10:34:20Z-
dc.date.issued2016-08-
dc.identifier.other000000136264-
dc.identifier.urihttps://hdl.handle.net/10371/132875-
dc.description학위논문 (석사)-- 서울대학교 대학원 : 의학과 해부학전공, 2016. 8. 이왕재.-
dc.description.abstractGV1001 derived from the human telomerase reverse transcriptase (hTERT) sequence is a peptide vaccine for the treatment of pancreatic cancer. The preclinical data clearly showed immunogenicity of GV1001 in patients with pancreatic cancer supported by the synergy of gemcitabine with cancer vaccines and the other positive immunomodulatory effects of gemcitabine. Even though it is reported that GV1001 may block weight loss of cancer patients and improve general condition after treatment of gemcitabine, but there are insufficient evidences so far. For this reason, we evaluate the preventive effect of GV1001 on gemcitabine-induced weigh loss in xenograft animal model. There was definite body weight loss and muscle weight loss of tumor-bearing mice by the treatment of gemcitabine. However, it was recovered by the treatment of gemcitabine with GV1001. In addition, we compared skeletal muscle proliferation and differentiation upon the treatment of gemcitabine with or without GV1001. When skeletal muscle cells were treated with gemcitabine only, the decrease of myogenesis was observed. The decrease is ameliorated by the co-treatment of GV1001. Upon investigation, the results demonstrate that GV1001 effectively prevents the loss of weight and the decrease in skeletal muscle proliferation and regeneration by gemcitabine.-
dc.description.tableofcontentsIntroduction 1

Materials and Methods 5
Cell culture 5
Cell proliferation and cytotoxicity assay 5
Cell cycle analysis 6
Real-time Polymerase Chain Reaction (qPCR) 7
Western blot analysis 8
Enzyme-Linked Immunosorbent Assay (ELISA) 9
Animals 10
Establishment of pancreatic cancer xenograft model and treatment 10
Measurement of tumor size, body weight, muscle weight and food intake 11
Statistical analysis 11

Results 13
GV1001 treatment slightly alleviates cytotoxic effect and inhibition of cell proliferation caused by gemcitabine 13
The mRNA and protein levels of myogenesis markers were elevated by GV1001 18
GV1001 relieves the increase in protein level of myostatin caused by TNF-α and IFN-γ 23
Gemcitabine-induced weight and muscle loss was prevented by combined treatment with GV1001 in BALB/c nude mice pancreatic cancer xenograft model 27

Discussion 33

References 37

Abstract in Korean 47
-
dc.formatapplication/pdf-
dc.format.extent932374 bytes-
dc.format.mediumapplication/pdf-
dc.language.isoen-
dc.publisher서울대학교 대학원-
dc.subjectcachexia-
dc.subjectgemcitabine-
dc.subjectGV1001-
dc.subjectmuscle wasting-
dc.subject.ddc610-
dc.titlePreventive effect of GV1001 on gemcitabine-induced pancreatic cancer cachexia-
dc.title.alternativeGemcitabine에 의해 유도된 췌장암 악액질에 미치는 GV1001의 예방 효과-
dc.typeThesis-
dc.description.degreeMaster-
dc.citation.pages48-
dc.contributor.affiliation의과대학 의학과-
dc.date.awarded2016-08-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Dept. of Medicine (의학과)Theses (Master's Degree_의학과)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse